Growth hormone secretagogue: difference between revisions
Diff·revision 13 → 14·17:02, 27 Jun 2025
Difference between revision 13 and revision 14 of Growth hormone secretagogue. 8 lines changed; the page grew by 875 bytes.
| Revision 13 — 04:27, 3 Jun 2025 Chromatokid (talk) state which receptor subtype the binding data refers to 3,620 bytes ±0 | Revision 14 — 17:02, 27 Jun 2025 CiteBot (talk) bot: sort category members 4,495 bytes +875 | ||
|---|---|---|---|
| 29 | They are prohibited in competitive sport under anti-doping rules, which is a regulatory fact rather than a safety statement.{{r|molitch2011}} | 29 | They are prohibited in competitive sport under anti-doping rules, which is a regulatory fact rather than a safety statement.{{r|molitch2011}} |
| 30 | 30 | ||
| + | 31 | == Material in research supply == | |
| + | 32 | These compounds are among the most commonly offered research peptides, and the documentary considerations are those set out at [[Certificate of analysis]] and [[Peptide content]]: a purity figure without content and water does not establish how much peptide a vial contains.{{r|usp1503}} | |
| + | 33 | ||
| + | 34 | Several are short peptides and are correspondingly easier to synthesise at high purity than the incretin analogues, which is reflected in typical reported purity figures. That is a property of the chemistry rather than of any supplier.{{r|reports}} | |
| + | 35 | ||
| 31 | == References == | 36 | == References == |
| 32 | {{reflist}} | 37 | {{reflist}} |
| 33 | <ref name="sigalos2018">Sigalos JT, Pastuszak AW. "The safety and efficacy of growth hormone secretagogues." ''Sexual Medicine Reviews'' 6(1):45–53 (2018). PMID 28526632.</ref> | 38 | <ref name="sigalos2018">Sigalos JT, Pastuszak AW. "The safety and efficacy of growth hormone secretagogues." ''Sexual Medicine Reviews'' 6(1):45–53 (2018). PMID 28526632.</ref> |
| 34 | <ref name="molitch2011">Molitch ME, Clemmons DR, Malozowski S, et al. "Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline." ''Journal of Clinical Endocrinology and Metabolism'' 96(6):1587–1609 (2011). PMID 21602453.</ref> | 39 | <ref name="molitch2011">Molitch ME, Clemmons DR, Malozowski S, et al. "Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline." ''Journal of Clinical Endocrinology and Metabolism'' 96(6):1587–1609 (2011). PMID 21602453.</ref> |
| + | 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| + | 41 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| 35 | 42 | ||
| 36 | == See also == | 43 | == See also == |
| ⋮ | ⋮ | ||
| 39 | * [[Sermorelin]] | 46 | * [[Sermorelin]] |
| 40 | * [[Tesamorelin]] | 47 | * [[Tesamorelin]] |
| + | 48 | * [[Research use only]] | |
| 41 | 49 | ||
| 42 | {{DEFAULTSORT:Growth hormone secretagogue}} | 50 | {{DEFAULTSORT:Growth hormone secretagogue}} |